Skip to main content

Table 2 Market shares* of types of oral hypoglycemic agents by country (2002 to 2012)

From: Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand

 

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

Brazil retail

           

Alpha-glucosidase inhibitors

2.18

2.12

2.06

1.90

2.03

1.89

1.55

1.45

1.21

0.81

0.62

Biguanides

34.56

37.50

40.94

43.61

45.70

48.61

49.55

49.56

51.39

54.21

57.53

DPP4 inhibitors

0

0

0

0

0

0.77

2.25

2.70

2.48

2.43

2.77

Fixed dose combinations**

1.51

4.35

6.87

8.29

9.04

8.50

9.26

10.07

9.50

8.32

7.60

Non-sulfonylurea secretagogues

3.55

3.58

3.28

2.94

2.76

2.19

1.55

1.25

0.98

0.58

0.33

Thiazolidinediones

0.73

0.86

0.93

1.14

1.55

1.34

0.99

0.93

0.76

0.47

0.46

Sulfonylureas

57.48

51.60

45.93

42.12

38.92

36.70

34.85

34.04

33.68

33.19

30.69

China hospital

           

Alpha-glucosidase inhibitors

10.50

13.48

16.65

18.41

19.76

21.06

21.95

23.16

25.48

26.94

27.35

Biguanides

45.41

43.48

39.27

38.03

37.34

36.57

35.68

34.31

32.93

33.22

34.64

DPP4 inhibitors

0

0

0

0

0

0

0

0

0.01

0.06

0.15

Fixed dose combinations**

0

0

0

0

0

0.01

0.03

0.15

0.21

0.13

0.15

Non-sulfonylurea secretagogues

2.26

3.85

5.58

6.98

8.31

10.33

12.05

13.72

14.72

15.16

14.13

Thiazolidinediones

0.37

0.66

0.93

1.26

2.35

2.99

3.31

3.79

3.82

3.30

2.79

Sulfonylureas

41.45

38.54

37.56

35.32

32.24

29.04

26.98

24.88

22.83

21.19

20.80

Thailand hospital

           

Alpha-glucosidase inhibitors

1.37

1.12

1.01

1.02

1.17

1.27

1.29

1.34

1.29

1.16

1.09

Biguanides

41.79

45.92

48.30

49.27

50.45

52.09

54.78

55.11

55.26

55.00

56.63

DPP4inhibitors

0

0

0

0

0

0

0.08

0.23

0.41

0.62

0.71

Fixed dose combinations**

0

0

0.01

0.05

0.08

0.12

0.20

0.31

0.40

0.49

0.68

Non-sulfonylurea secretagogues

0.15

0.15

0.14

0.14

0.16

0.17

0.16

0.16

0.15

0.14

0.15

Thiazolidinediones

0.43

0.54

0.71

0.81

1.18

1.28

1.38

1.61

1.90

2.15

2.33

Sulfonylureas

56.26

52.27

49.83

48.71

46.96

45.06

42.11

41.25

40.58

40.45

38.41

Thailand retail

           

Alpha-glucosidase inhibitors

1.83

1.58

1.30

1.11

1.98

1.92

1.69

1.73

2.28

1.86

2.75

Biguanides

35.12

32.10

37.81

42.00

42.82

43.16

39.94

43.41

39.71

41.17

40.81

DPP4 inhibitors

0

0

0

0

0

0

0

0

0.16

0.62

1.31

Fixed dose combinations**

0

0

0

0

0

0

0

0.09

0.06

0.05

0.27

Non-sulfonylurea secretagogues

0

0

0.19

0.22

0.38

0.41

0.47

0.50

0.50

0.43

0.50

Thiazolidinediones

0.23

0.50

0.54

0.62

0.66

0.58

0.54

1.43

1.75

1.74

2.37

Sulfonylureas

62.82

65.82

60.16

56.06

54.16

53.93

57.35

52.83

55.54

54.12

52.00

  1. *Market share is the percentage of the total market volume based on volume sold in standard units per 1000 population. IMS Health defines a standard unit as the smallest common dose of a product form: one tablet or capsule for oral formulations.
  2. **Fixed dose combinations include the following: cinnamomum loureirii & glipizide & metformin; glibenclamide & metformin; gliclazide & metformin; glimepiride & metformin; glimepiride & rosiglitazone; glipizide & metformin; metformin & nateglinide; metformin & pioglitazone; metformin & rosiglitazone; metformin & saxagliptin; metformin & sitagliptin; metformin & vildagliptin.
Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us